History icon
The French Atomic Energy Commission (CEA) has been studying the impact of radiation on DNA for several decades. This research has resulted in a good understanding of the essential DNA repair mechanisms.
Recently, a set of innovative biomarkers was developed providing a complete functional signature for these mechanisms. This signature is now exploited as part of powerful tools for personalized cancer treatment.

DNA Repair meets diagnostics

LXRepair is a CEA spin-off building on over 25 years' research into the science behind DNA repair mechanisms and in vitro diagnostics for cancer.
Awards icon
Biovision Catalyser Awards winner 2013
Ministry of High Education, Reasearch and Innovation Awards Company of Innovative Technology
Stéphane ATALBA, LXRepair CEO, PhD, ESCP

Stéphane ALTABA

Chief Executive Officer, PhD, ESCP
Stéphane Altaba, 55 year-old, holds a PhD in bio­techno­logy (INPL) and a degree from the École Supé­rieure de Com­merce de Paris (ESCP-Europe). From 1994 and for more than 12 years, Stéphane Altaba held various respon­sibi­li­ties within the Sanofi Group: from R&D to Indus­trial Affairs, then Busi­ness Develop­ment. The last posi­tion he held at Sanofi was Group Director of Onco­logy Agree­ments and Licen­sing.
During his 9 years with Nordic Pharma, he esta­bli­shed several strate­gic partner­ships with other pharma­ceu­ti­cal com­pa­nies and set up a net­work of sub­si­diaries in Europe for the marke­ting of the com­pany's main pro­ducts.
In 2015, he joined Genomic Vision a mole­cular diagnos­tics com­pany where he was a member of the board and Chief Ope­ra­ting Officer. He success­fully re­organi­zed the com­pany around the main markets of interest, in diagnos­tics, bio­produc­tion and preci­sion medi­cine, which led to a signi­fi­cant growth in sales.


President, Chief Scientific Officer
Sylvie Sauvaigo found­ed LX­Repair, a CEA’s spin-off, in 2013. She is res­pon­si­ble for LX­Repair R&D and clin­i­cal pro­grams.
She is gra­d­u­at­ed of the INSA school of En­gi­neer­ing and has a strong back­ground in chemist­ry and bio­chemist­ry. She got her PhD from Uni­ver­si­ty of Gre­no­ble.
Pas­sion­ate about in­no­va­tion and tech­no­log­i­cal break­throughs she start­ed her car­ri­er as Pro­ject Man­ag­er at Cis bio inter­na­tion­al where she de­vel­oped in­no­va­tive diag­nos­tic as­says for infec­tious dis­eases. She joined CEA where she fo­cused on DNA dam­age and DNA Re­pair. She led a group in the Tech­nolo­gies for health pro­gram to de­vel­op first-of-its-kind tech­nology for DNA Repair char­ac­ter­­i­za­tion.
Dr Thierry MAILLET, LXRepair Diagnostic & QMS Manager

Dr Thierry MAILLET

Diagnostic & Quality Management System Manager
Thierry Maillet joined LXRepair in Febru­ary 2018 as Di­ag­nos­tic De­vel­op­ment and Qual­i­ty Man­ag­er.
Thierry earned a PhD in Molec­u­lar Bio­chem­istry and Bio­physics from the Uni­ver­si­ty of Or­léans.
Thierry has over 25 years of ex­pe­ri­ence in the in vit­ro di­ag­nos­tic in­dus­try.
Af­ter 18 years at Stago as De­vel­op­ment and Man­u­fac­tur­ing man­ag­er, he spent near­ly 5 years at the French reg­u­la­tory au­thor­i­ty for health prod­ucts safe­ty as a Cer­ti­fied Inspector.
Sarah LIBERT, LXRepair Lab Manager Quality, Service, Production, R&D Engineer


R&D Engineer, Lab Manager Quality, Service, Production
Sarah Libert joined LX­Re­pair in 2014 as re­search en­gi­neer.
She has a Mas­ter De­gree in biotech­nol­o­gy from the Uni­ver­si­ty of Sci­ence of Gre­no­ble. She cur­rent­ly holds the po­si­tion of ser­vice and pro­duc­tion man­a­ger and is ac­tive­ly in­volved in im­ple­men­ta­tion of qual­i­ty man­age­ment sys­tem and R&D pro­grams.
Through­out her ca­reer, she has de­vel­oped skills in cell cul­ture, molec­u­lar bi­ol­o­gy and biochips.
Prior to join LXRepair, she spent 7 years work­ing in a biotech­nol­o­gy start-up en­vi­ron­ment at Mellitech.
Dr Giovanna MUGGIOLU, LXRepair Project Leader

Dr Giovanna MUGGIOLU

R&D Project Leader
Dr. Giovanna Muggiolu joined LXRepair in Novem­ber 2017 as Head of Re­search and De­vel­op­ment. Her re­search fo­cus­es on de­fining a DNA Repair enzyma­tic sig­na­ture that char­ac­ter­izes the pa­tient’s re­sponse to ra­dio and chemo­ther­a­py. Her pri­or re­search fo­cused on molec­u­lar mech­a­nisms in­duced by ion­iz­ing ra­di­a­tion for emerg­ing can­cer ther­a­pies. She re­ceived her M.A. from the Uni­ver­si­ty of Tu­rin in Med­i­cal Biotech­nolo­gies and PhD from Bor­deaux Uni­ver­si­ty in Cel­lu­lar Bi­ol­o­gy and Physio­patho­lo­gy.
Bertrand TREILLARD, LXRepair Quality, R&D Engineer


R&D & Quality Engineer
Bertrand Treillard joined LX­Re­pair in Septem­ber 2017 as an En­gi­neer in Re­search and De­vel­op­ment and is par­tic­u­lar­ly in­volved in the de­vel­op­ment of LXRe­pair di­ag­nos­tic tests. He spe­cial­izes in biotech­nol­o­gy and molec­u­lar di­ag­nos­tics. Pri­or to join­ing LX­Re­pair, Bertrand worked on the tech­ni­cal de­vel­op­ment of an in vit­ro di­ag­nos­tic test at Im­munID, al­low­ing to ob­tain CE mark­ing for the test and CLIA cer­ti­fi­ca­tion for the Lab. ­
Xavier Tatin, LXRepair PhD Student

Xavier TATIN

PhD student
Xavier Tatin joined LX­Re­pair in 2018 and he is cur­rent­ly do­ing a PhD in col­lab­o­ra­tion with a CEA lab. Grad­u­at­ed in 2017 from Agro­Paris­Tech he also holds a master’s de­gree in biotech­nol­o­gy. His doc­tor­al work is focus­ed on the de­vel­op­ment and the val­i­da­tion of a new en­zy­mat­ic as­say for the char­ac­ter­i­za­tion of DNA dou­ble-strand breaks re­pair.
He also worked at the Uni­ver­si­ty of Otago in New Zealand and at Nova South­eastern Uni­ver­si­ty (FL, USA).
Board members
Gwenaël HAMON, investment chief at KREAXI

Gwenaël HAMON

Investment chief at KREAXI
Gwenaël is In­vest­ment Di­rec­tor at KREAXI. He start­ed his ca­reer in 2009 within the Si­parex Group, as part of the In­no­va­tion Cap­i­tal in Lyon, be­fore join­ing the Kreaxi’s team in De­cem­ber 2012. Gwenaël has de­vel­oped an ex­per­tise in in­no­va­tive tech­nol­o­gy com­pa­nies, par­tic­u­lar­ly in the field of health, bi­ol­o­gy and chem­istry. Amoe­ba, Ther­anexus, KREAXI on the Board of Di­rectors / Su­per­vi­so­ry Board of sev­er­al com­pa­nies in­clud­ing Nosopharm, Ther­anexus, Di­a­be­loop, Faben­tech, Med­i­cal 360, I-TEN.
Gwenaël is a grad­u­ate en­gi­neer from the Ecole Na­tionale Supérieure des Arts et Métiers (Cluny, Paris), and com­plet­ed his stud­ies by the MS En­gi­neer­ing Fi­nance of EM Lyon.
Celia Hart, PhD, MBA Partner at Supernova Invest

Celia HART

PhD, MBA Partner at Supernova Invest
Celia has more than 20 years of ex­pe­ri­ence in the chem­i­cal and biotech­nol­o­gy sec­tor. She joined CEA In­vestisse­ment (now Su­per­no­va In­vest) in 2005 and has since car­ried out the in­vest­ments in sev­er­al com­pa­nies op­er­at­ing main­ly in life sci­ences. She serves (or has served) on the Boards of sev­er­al com­pa­nies in­clud­ing Al­ga­ia, Bioax­i­al, Di­abe­loop, Fer­men­talg, Ker­a­no­va, Uromems and Ther­anexus.
Pri­or to that Celia main­ly worked for Cam­bridge An­ti­body Tech­nol­o­gy one of the most suc­cess­ful UK biotech­nol­o­gy com­pa­nies (now Med­im­mune fol­lowing its ac­qui­si­tion by As­tra Zene­na) hold­ing dif­fer­ent man­ag­ing and prod­uct de­vel­op­ment po­si­tions in­clud­ing Head of Lead Op­ti­miza­tion. She was in­volved in the de­vel­op­ment of sev­er­al ther­a­peu­tic an­ti­bod­ies in in­clud­ing some in col­lab­o­ra­tion with in­ter­na­tion­al biotech­nol­o­gy or phar­ma­ceu­ti­cal part­ners.
Celia holds a de­gree in Chem­istry from the Uni­ver­si­ty of Gene­va (Switzer­land), a Ph.D. from the Uni­ver­si­ty of Ox­ford (UK) and an MBA from Greno­ble Ecole de Man­age­ment (France).
Sophie MANUEL, cardiologist


Sophie Manuel is an ex­pe­ri­enced Car­di­ol­o­gist. She also works as an au­ricu­lo-ther­a­pist in can­cerol­o­gy or as an clin­i­cal and mar­ket­ing ex­pert.
François Xavier Desforges, experienced Manager of innovative start-ups companies

FX Desforges

FX Desforges is an experienced Man­ager of High Techno­lo­gies/In­no­va­tive start-ups com­pa­nies in var­i­ous mar­kets (Health, Mar­itime, In­stru­men­ta­tion, ….) with a broad ex­pe­ri­ence in var­i­ous do­mains (Sales & Mar­ket­ing of In­no­va­tive Pro­ducts, Fi­nance, Busi­ness Plan, HR, R&D, …). Re­cent­ly, he was CEO of Presto­diag SAS, a di­ag­nos­tic com­pa­ny in food safe­ty and pre­vi­ous­ly CEO of Ge­newave SAS which merged with Mo­bidiag in 2014.
François Xavier grad­u­at­ed from Ecole Nor­male Su­perieure in 1983 and earned a PhD from Uni­ver­si­ty of Limoges in 1989.
bpifrance, LXRepair's partner
Preuve du concept, LXRepair's partner
CLARA, Cancérologie Lyon Auvergne Rhône-Alpes, LXRepair's partner
Medic@lps, LXRepair's partner
Institut de cancérologie de la Loire Lucien Neuwirth, LXRepair's partner
LYONBIOPOLE, LXRepair's partner
Université de Lyon, LXRepair's partner
CHU Grenoble Alpes, LXRepair's partner
Hopitaux de Lyon, LXRepair's partner
La Région Auvergne-Rhône-Alpes, LXRepair's partner

LXRepair SAS

5, avenue du Grand Sablon
38700 La Tronche